BioSpace News Archive

OpGen, Inc. today announced prospective clinical data on the Unyvero LRT BAL presented during a webinar held on June 29, 2021, and data presented at the virtual World Microbe Forum, June 20-24, 2021.

Cidara Therapeutics, Inc. today announced that it will present new analyses in four presentations, including an oral presentation on rezafungin, at the 31 st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), taking place virtually from July 9-12, 2021.

Journey Medical Corporation, a partner company of Fortress Biotech, Inc., announced an agreement with Dr. Reddy’s Laboratories Ltd. for the collaborative development and commercialization of the DFD-29 program for the treatment of rosacea.

Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, today announced that two abstracts for Lomecel-B, the Company’s investigational cell therapy being developed to treat aging-related life-threatening conditions, have been accepted for poster presentation at the Gerontological Society of America (GSA) 2021 Annual Scientific Meeting,

I-Mab today announced that it was ranked among the top companies by leading global financial publication Institutional Investor in both the “Honored Companies” and “Best CFO” categories, according to its 2021 All-Asia Executive Team survey.

Sirnaomics, Inc. today announced dose administration for the first patient in a Phase 2b study of the company’s drug candidate, STP705, for the treatment of squamous cell skin cancer in situ (isSCC).

Progenity, Inc. announced the appointment of Surbhi Sarna to its board of directors effective July 1, 2021.

Diffusion Pharmaceuticals Inc. today announced topline results from the Company’s Phase 1 trial of its lead product candidate, trans sodium crocetinate (“TSC”).

Embera NeuroTherapeutics Announces First Subject Dosed in Phase 2a Study of EMB-001 in Smoking Cessation

Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, announced that data on its lead compound, devimistat, has been selected for an oral presentation at the 2021 European Society of Medical Oncology World Gastrointestinal Congress, taking place June 30 through July 3, 2021.